Search bioRxiv⌕ Search

bioRxiv · 10.1101/2024.02.28.582582

DeepSP: Deep Learning-Based Spatial Properties to Predict Monoclonal Antibody Stability

Abstract

Therapeutic antibody development, manufacturing, and administration face challenges due to high viscosities and aggregation tendencies often observed in highly concentrated antibody solutions. This poses a particular problem for subcutaneous administration, which requires low-volume and high-concentration formulations. The spatial charge map (SCM (mAbs, 8 (1) (2015), pp. 43-48)) and spatial aggregation propensity (SAP (PNAS. 2009; 106:11937-42) are two computational techniques proposed from previous studies to aid in predicting viscosity and aggregation, respectively. These methods rely on structural data derived from molecular dynamics (MD) simulations, which are known to be time-consuming and computationally demanding. DeepSCM (CSBJ. 2022, 20:2143-2152), a deep learning surrogate model to predict SCM scores in the entire variable region, was used to screen high-concentration antibody viscosity. DeepSCM is solely based on sequence information, which facilitates high throughput screening. This study further utilized a dataset of 20,530 antibody sequences to train a convolutional neural network deep learning surrogate model called Deep Spatial Properties (DeepSP). DeepSP directly predicts SAP and SCM scores in different domains of antibody variable regions based solely on their sequences without performing MD simulations. The linear correlation coefficient (R) between DeepSP scores and MD-derived scores for 30 properties achieved values between 0.76 and 0.96 with an average of 0.87 on the test set (N=2053). DeepSP was employed as features to build machine learning models to predict the aggregation rate of 21 antibodies. We observed remarkable results with R = 0.97 and a mean squared error (MSE) of 0.03 between the experimental and predicted aggregation rates, leave-one-out cross-validation (LOOCV) yielded R = 0.75 and MSE = 0.18, which is similar to the results obtained from the previous study using MD simulations. This result demonstrates that the DeepSP approach significantly reduces the computational time required compared to MD simulations. The DeepSP model enables the rapid generation of 30 structural properties that can also be used as features in other research to train machine learning models for predicting various antibody properties, such as viscosity, aggregation, or other properties that can influence their stability, using sequences only. The code and parameters are freely available at https://github.com/Lailabcode/DeepSP HighlightsO_LIDeep learning applied to develop a surrogate model (DeepSP) to rapidly predict 30 spatial properties of monoclonal antibodies that are usually calculated from MD simulations, using only sequences. C_LIO_LIThe DeepSP models achieved a linear correlation ranging between 0.76 and 0.96 with an average of 0.87, between the actual (MD simulation) and predicted score for all properties. C_LIO_LIDeepSP features were employed to build a model to predict aggregation rates of antibodies obtained from a previous study. A strong correlation of 0.97, and LOOCV correlation of 0.75 were achieved between the actual and predicted aggregation rates. C_LIO_LIDeepSP can be employed to generate antibody-specific features that can be used to train different machine learning models to predict antibody stability. C_LI

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Kalejaye, L. A., Wu, I.-E., Terry, T., Lai, P.-K.. 2024-03-03. DeepSP: Deep Learning-Based Spatial Properties to Predict Monoclonal Antibody Stability. https://doi.org/10.1101/2024.02.28.582582

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Design of colipids with controlled lateral distance of head group moieties for targeting strategies in the field of lipid-based nanoparticles

Lipid nanoparticles and liposomes are nanoparticle drug formulations which are firmly established in clinics. In order to expand their application and improve efficacy, surface modifications can be a key strategy, especially for cell specific targeting. Targeting can be achieved by integrating ligand functionalized lipids or lipidoids on the nanoparticle surface. In this case, not solely the targeting ligand itself, but also the structure of the whole targeting lipid/lipidoid can affect the interaction of the targeting ligand with the binding motive on cells. Especially, distal spacer structures between lipid anchor and ligand unit, often composed of polyethylene glycol chains, provide a certain distance of the ligand from the nanoparticle surface. A concept which is currently neglected is the control of the lateral distance between ligand structures on the nanoparticle. Herein we investigated the possibility to design lipidoids with a lateral spacer composed of polyethylene glycol units. We synthesized and characterized different lipidoids which provide a primary amine in the head group for possible ligand coupling. In our model lipidoids the head groups were functionalized with a paramagnetic probe to apply electron paramagnetic resonance (EPR) methods for the characterization of the lipidoid interaction with model nanoparticles, in our case liposomes. Continuous wave EPR was used to study the efficiency of the novel lipidoids to integrate into lipid bilayers of model liposomes, which was shown to depend on lipidoid structure and liposome composition. Furthermore, using double electron-electron resonance (DEER), we observed lipidoid conformational changes occurring upon integration into liposomes.

biophysics↗

Binding mechanisms of therapeutic antibodies to human claudin-18.2

Claudin-18.2 (CLDN18.2) is a tight junction component with highly restricted expression in the paracellular space of nonmalignant gastric epithelial cells. It becomes accessible on tumor cell surface during malignant transformation, making CLDN18.2 an attractive target for targeted therapies against gastric cancer. Recently, zolbetuximab has become the first FDA-approved monoclonal antibody that targets CLDN18.2 in advanced gastric cancer, and others like osemitamab have entered phase 3 clinical trials. However, the high-resolution structure of CLDN18.2 is lacking, and how CLDN18.2 is recognized by therapeutic antibodies remains undefined. Here, we report cryo-EM structures of human claudin-18.2 (hCLDN18.2) in complex with the Fab fragments of zolbetuximab and osemitamab, revealing the structure of hCLDN18.2 and its binding mechanism to the therapeutic antibodies. Further analyses reveal that three residues in the first extracellular loop of hCLDN18.2 that are different from human claudin-18.1 (hCLDN18.1) play a critical role in antibody binding. Our data elucidate the structural basis for selective binding of therapeutic antibodies to hCLDN18.2, which should aid rational design of next-generation immunotherapies targeting hCLDN18.2.

biophysics↗

Structural relationships between the SLC12 cotransporter C-terminal domain, universal stress proteins and adenylating enzymes

Several SLC12 cotransporters bind ATP in a cytoplasmic C-terminal domain (CTD). We analysed 16,192 CTD-containing SLC12 sequences and compared 42,845 representative structures to examine the relationship between this nucleotide site, universal stress proteins (USPs) and adenylating enzymes. In phosphorylated NKCC1, D891 and D927 lie near the ATP phosphate chain, while R801 and K889 form a basic phosphate-binding clamp. NKCC1 retains this arrangement, whereas KCC paralogs replace or lose several corresponding groups. In structural comparisons with USP and adenylating-enzyme references, both CTD lobes score between universal stress proteins and EC-annotated domains, and the two lobes form separate lineages that include bacterial transporters. Lobe-specific and nucleotide-frame comparisons place ATP in the corresponding structural region used for -phosphate chemistry by catalytic members of this fold. Published work on UspG provides a precedent for protein-bound AMP in a natural USP. In the examined SLC12 structures and USP models, candidate protein hydroxyls lack an in-line geometry for attack at ATP P. Protein adenylation would require a change in protein or nucleotide geometry, or a different acceptor. These results define a structural basis for testing conditional protein adenylation at SLC12 nucleotide sites. The required evidence is a covalent protein-AMP adduct, identification of its acceptor and measurement of the expected pyrophosphate coproduct, with soluble nucleotide analysis to distinguish accompanying ATP reactions.

biophysics↗